Skip to main content

Table 1 Baseline characteristics of patients

From: Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study

Baseline characteristic

Value (N = 187)

Age (years), median (range)

36.4 (18–64)

Gender, N (%)

 Male

108 (57.7%)

Primary diagnosis, N (%)

 Leukaemia

77 (41.2%)

  Acute lymphoblastic leukaemia

19

  Acute myeloid leukaemia

39

  Chronic myeloid leukaemia

7

  Myelodysplastic syndrome

12

 Lymphoma

66 (35.3%)

  Non-Hodgkin lymphoma

24

  Hodgkin lymphoma

42

 Other malignancies

16 (8.5%)

  Multiple myeloma

15

  Germ-cell tumour

1

 Non-malignancies

28 (14.9%)

  Aplastic anaemia

14

  Fanconi anaemia

1

  Myelofibrosis

2

  Red-cell aplasia

1

  Sickle-cell anaemia

1

  Thalassaemia

9

Type of transplant

 Autologous

65 (34.8%)

 Allogeneic

122 (65.2%)

  Related donor

15

  Unrelated donor

105

  Haplo-identical transplant

2

Stem cell source, N (%)

 Peripheral stem cells

166 (88.8%)

 Bone marrow cells

19 (10.1%)

 Bone marrow and peripheral stem cells

1 (0.5%)

 Umbilical cord bank

1 (0.5%)

Conditioning regimen intensity, N (%)

 Myeloablative

130 (69.5%)

 Reduced intensity

55 (29.4%)

 Reduced toxicity

1 (0.5%)

 None

1 (0.5%)

Baseline comorbidity, N (%)

 Cardiac disease

40 (21.4%)

 Endocrine disease

25 (13.3%)

 Kidney disease

10 (5.3%)

 Liver disease

6 (3.2%)

 Other

43 (22.9%)

GVHD, N (%)

 Acute

16 (8.6%)

 Chronic

31 (16.6%)

 Both acute and chronic

38 (20.3%)

 None

102 (54.5%)